MITOLOGICS

Their core work

MITOLOGICS is a French biotech SME focused on drug discovery for mycobacterial infections, contributing specialist capabilities in high-throughput compound screening and structural biology to identify and validate new drug targets. Their work concentrates on tuberculosis (TB) and non-tubercular mycobacteria (NTM) — two disease areas with severe unmet medical need and growing antibiotic resistance. They appear to work on enzymes unique to mycobacteria, notably mycothione reductase, which has no human equivalent and is therefore an attractive target for drugs with minimal off-target toxicity. Their role in research consortia is to advance candidate molecules from early screening toward first-in-human trials, bridging basic science and clinical development.

What they specialise in

How they've shifted over time

Both of MITOLOGICS' H2020 projects started simultaneously in 2019 and share identical keywords, which means there is no meaningful keyword shift to analyze — the early and recent periods overlap entirely. This pattern is consistent with a small, highly focused company that entered the EU research landscape with a well-defined niche rather than gradually expanding its scope. The absence of evolution is itself informative: MITOLOGICS is a specialist, not a generalist broadening its portfolio over time.

MITOLOGICS shows no change in focus — both projects are active 2019–2027 in the same disease area — suggesting a company that has committed deeply to mycobacterial drug discovery and is likely building toward clinical-stage assets rather than pivoting to new sectors.

How they like to work

MITOLOGICS has never coordinated an H2020 project, always participating as a specialist contributor inside consortia led by others — consistent with a small SME that brings a specific technology or screening capability rather than project management infrastructure. With 9 unique partners across 6 countries spread over just 2 projects, their network is modest but international. They appear to be brought into consortia for what they can do technically, not for their size or coordination experience.

MITOLOGICS has worked with 9 distinct consortium partners across 6 countries — a reasonable spread for two projects, suggesting the Respiri consortia are mid-sized, multi-national drug discovery collaborations. No geographic concentration is evident from the available data beyond France as home country.

What sets them apart

MITOLOGICS occupies a narrow but high-value niche: they bring high-throughput screening and structural biology expertise specifically tuned to mycobacterial targets — a combination that is rare among SMEs and directly relevant to the global TB drug pipeline. Their focus on mycothione reductase, an enzyme with no human equivalent, suggests they have proprietary assay capability or chemical matter in this target class that would be difficult to replicate quickly. For consortia building toward TB or NTM first-in-human trials, they represent a specialist plug-in that bridges biochemistry and early clinical development.

Highlights from their portfolio

• RespiriTB
  Their largest project by far (EUR 146,631), targeting tuberculosis — one of the world's leading infectious disease killers — with the goal of progressing a pre-new molecular entity and achieving a first-time-in-human milestone by 2027.
• RespiriNTM
  A companion project targeting non-tubercular mycobacteria (NTM), which are increasingly drug-resistant and affect immunocompromised patients; notable for running in parallel with RespiriTB, suggesting MITOLOGICS is part of a coordinated mycobacterial drug discovery platform.